Drug Guide

Generic Name

Desipramine Hydrochloride

Brand Names Pertofrane, Norpramin

Classification

Therapeutic: Antidepressant, Tricyclic

Pharmacological: Tricyclic Antidepressant (TCA)

FDA Approved Indications

  • Major depressive disorder

Mechanism of Action

Inhibits the reuptake of norepinephrine and serotonin, increasing their levels in the central nervous system, resulting in antidepressant effects.

Dosage and Administration

Adult: Typically, starting dose is 50-75 mg at bedtime, titrated up as needed, usual range 100-200 mg/day.

Pediatric: Use is generally not recommended in children and adolescents due to safety concerns.

Geriatric: Start with lower doses (e.g., 25 mg at bedtime) and titrate slowly, considering increased sensitivity and risk of side effects.

Renal Impairment: Use with caution; monitor and consider dose adjustments as renal function declines.

Hepatic Impairment: Use with caution; dose reduction may be necessary due to impaired metabolism.

Pharmacokinetics

Absorption: Well absorbed orally, with variable bioavailability.

Distribution: Widely distributed; crosses the blood-brain barrier and placenta.

Metabolism: Primarily hepatic via CYP2D6 to active metabolites and other pathways.

Excretion: Excreted mainly in urine.

Half Life: Approximately 12-24 hours, allowing for once or twice daily dosing.

Contraindications

  • Recent myocardial infarction
  • Use within 14 days of monoamine oxidase inhibitors (MAOIs)
  • Known hypersensitivity

Precautions

  • History of seizure disorder
  • Glaucoma
  • Urinary retention
  • Suicidality risk, especially in young adults
  • Elderly patients may be more susceptible to side effects

Adverse Reactions - Common

  • Dry mouth (Common)
  • Drowsiness (Common)
  • Dizziness (Common)
  • Constipation (Common)

Adverse Reactions - Serious

  • Cardiac arrhythmias (Serious, potentially life-threatening)
  • Seizures (Serious)
  • Hypotension (Serious)

Drug-Drug Interactions

  • MAO inhibitors – risk of serotonin syndrome and hypertensive crisis
  • Other CNS depressants – increased sedation
  • Anticholinergic agents – additive anticholinergic effects

Drug-Food Interactions

  • Alcohol – additive CNS depression and cardiovascular effects

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor heart rhythm via ECG, assess mental status and suicidality, monitor for anticholinergic effects.

Diagnoses:

  • Risk for cardiac arrhythmias
  • Risk for falls related to dizziness
  • Altered mental status

Implementation: Administer at bedtime to reduce sedation; instruct patient to avoid abrupt discontinuation; monitor for side effects.

Evaluation: Assess for therapeutic response and adverse effects; re-evaluate dosing as needed.

Patient/Family Teaching

  • Take medication exactly as prescribed; do not stop abruptly.
  • Report signs of cardiac issues, suicidal thoughts, or severe side effects.
  • Avoid alcohol and other CNS depressants.
  • Be aware of anticholinergic side effects like dry mouth and constipation.

Special Considerations

Black Box Warnings:

  • Increased risk of suicidality in children, adolescents, and young adults.

Genetic Factors: Metabolism via CYP2D6; poor metabolizers may have increased plasma levels.

Lab Test Interference: May affect blood glucose monitoring and certain cardiac assessments.

Overdose Management

Signs/Symptoms: Confusion, agitation, hallucinations, seizures, cardiac arrhythmias, coma.

Treatment: Supportive care, activated charcoal if recent ingestion, sodium bicarbonate for cardiac arrhythmias, and emergency resuscitation as needed.

Storage and Handling

Storage: Store at room temperature, 20-25°C (68-77°F), away from light and moisture.

Stability: Stable under recommended storage conditions; check expiration date regularly.

This guide is for educational purposes only and is not intended for clinical use.